SCHEMBL12401425

SCHEMBL12401425

C=CCN(CC(C)(C)C=O)S(=O)(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
RAB9A P51151 2/20 0.42
ESR1 P03372 1/20 0.42
CNR2 P34972 3/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 2/20 0.41
ALOX12 P18054 2/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
NPSR1 Q6W5P4 1/20 0.39
PKM P14618 1/20 0.39
CNR1 P21554 1/20 0.39
NR1I2 O75469 2/20 0.39
HTT P42858 2/20 0.38
S1PR1 P21453 1/20 0.38
TSHR P16473 1/20 0.38
ESR2 Q92731 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12372417 0.87 C5AR1 (0.46) C5AR1RAB9AESR1CNR2KMT2A
SCHEMBL12372418 0.82 RAB9A (0.47) C5AR1RAB9AESR1CNR2KMT2A
SCHEMBL4262910 0.81 ESR1 (0.53) C5AR1RAB9AESR1CNR2KMT2A
SCHEMBL2281838 0.80 RAB9A (0.45) C5AR1RAB9AESR1CNR2KMT2A
SCHEMBL11675019 0.79 LMNA (0.53) C5AR1RAB9AESR1CNR2KMT2A
SCHEMBL12372411 0.77 RAB9A (0.45) C5AR1RAB9AESR1CNR2KMT2A
SCHEMBL11095184 0.74 CNR2 (0.59) CNR2KMT2AMEN1MAPTCNR1
SCHEMBL5324937 0.73 RAB9A (0.63) C5AR1RAB9AESR1KMT2AMEN1
SCHEMBL8780976 0.72 TDP1 (0.54) C5AR1RAB9AESR1CNR2KMT2A
SCHEMBL30212577 0.72 ESR1 (0.44) C5AR1RAB9AESR1CNR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008298-B2 Pyrrolopyrazine kinase inhibitors Roche Palo Alto (US) 2011-08-30 US disclosed
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors SYK, ZAP70, TYK2 C5AR1 2431/4885RAB9A 2723/4885ESR1 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.